Lisata Therapeutics to Be Acquired by Kuva Labs for $5.00 Cash Plus $1.00 CVR
Summary
Lisata Therapeutics has announced a definitive agreement to be acquired by Kuva Labs for $5.00 per share in cash, along with a non-tradeable Contingent Value Right (CVR) worth up to an additional $1.00 per share. The CVR is tied to a regulatory milestone for certepetide within seven years. This news provides the crucial financial terms of the acquisition, following the Dow Jones Newswires report on March 6th that a definitive agreement had been reached. The tender offer structure, which includes a merger under Delaware Section 251(h) without a shareholder vote, indicates a clear path to closing. This transaction offers a significant premium to shareholders and fundamentally alters the investment outlook for LSTA, shifting focus to the deal's completion and the potential value of the CVR.
At the time of this announcement, LSTA was trading at $5.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.9M. The 52-week trading range was $1.81 to $4.89. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.